Literature DB >> 25131449

HDL and cognition in neurodegenerative disorders.

David A Hottman1, Dustin Chernick2, Shaowu Cheng1, Zhe Wang1, Ling Li3.   

Abstract

High-density lipoproteins (HDLs) are a heterogeneous group of lipoproteins composed of various lipids and proteins. HDL is formed both in the systemic circulation and in the brain. In addition to being a crucial player in the reverse cholesterol transport pathway, HDL possesses a wide range of other functions including anti-oxidation, anti-inflammation, pro-endothelial function, anti-thrombosis, and modulation of immune function. It has been firmly established that high plasma levels of HDL protect against cardiovascular disease. Accumulating evidence indicates that the beneficial role of HDL extends to many other systems including the central nervous system. Cognition is a complex brain function that includes all aspects of perception, thought, and memory. Cognitive function often declines during aging and this decline manifests as cognitive impairment/dementia in age-related and progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. A growing concern is that no effective therapy is currently available to prevent or treat these devastating diseases. Emerging evidence suggests that HDL may play a pivotal role in preserving cognitive function under normal and pathological conditions. This review attempts to summarize recent genetic, clinical and experimental evidence for the impact of HDL on cognition in aging and in neurodegenerative disorders as well as the potential of HDL-enhancing approaches to improve cognitive function.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25131449      PMCID: PMC4252583          DOI: 10.1016/j.nbd.2014.07.015

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  245 in total

1.  Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study.

Authors:  Archana Singh-Manoux; David Gimeno; Mika Kivimaki; Eric Brunner; Michael G Marmot
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-30       Impact factor: 8.311

2.  Cholesteryl ester transfer protein in human brain.

Authors:  J J Albers; J H Tollefson; G Wolfbauer; R E Albright
Journal:  Int J Clin Lab Res       Date:  1992

Review 3.  Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.

Authors:  Per Svenningsson; Eric Westman; Clive Ballard; Dag Aarsland
Journal:  Lancet Neurol       Date:  2012-08       Impact factor: 44.182

4.  Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

Authors:  Stephen J Nicholls; H Bryan Brewer; John J P Kastelein; Kathryn A Krueger; Ming-Dauh Wang; Mingyuan Shao; Bo Hu; Ellen McErlean; Steven E Nissen
Journal:  JAMA       Date:  2011-11-16       Impact factor: 56.272

5.  Mechanistic studies on metabolic interactions between gemfibrozil and statins.

Authors:  Thomayant Prueksaritanont; Jamie J Zhao; Bennett Ma; Brad A Roadcap; Cuyue Tang; Yue Qiu; Lida Liu; Jiunn H Lin; Paul G Pearson; Thomas A Baillie
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

6.  Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.

Authors:  Arthur J Bergman; Gail Murphy; Joanne Burke; Jamie J Zhao; Robert Valesky; Lida Liu; Kenneth C Lasseter; Weili He; Thomayant Prueksaritanont; Yue Qiu; Alan Hartford; Jose M Vega; John F Paolini
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

Review 7.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

8.  Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease.

Authors:  Giulio Scigliano; Gabriele Ronchetti; Floriano Girotti; Massimo Musicco
Journal:  Parkinsonism Relat Disord       Date:  2008-06-16       Impact factor: 4.891

9.  The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.

Authors:  Radosveta P Koldamova; Iliya M Lefterov; Matthias Staufenbiel; Darren Wolfe; Shaohua Huang; Joseph C Glorioso; Michael Walter; Michael G Roth; John S Lazo
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

10.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

View more
  48 in total

1.  Sex-dependent difference in the relationship between adipose-tissue cholesterol efflux and estradiol concentrations in young healthy humans.

Authors:  Fatima Iqbal; William J Durham; Ayyash Melhem; Saleem Raslan; Tony T Tran; Traver J Wright; Rabia Asghar; Ken Fujise; Elena Volpi; Labros Sidossis; Nicola Abate; Melinda Sheffield-Moore; Demidmaa Tuvdendorj
Journal:  Int J Dev Neurosci       Date:  2017-07-12       Impact factor: 2.457

2.  ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.

Authors:  Angela W Corona; Nathan Kodoma; Brad T Casali; Gary E Landreth
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-15       Impact factor: 4.147

3.  The Alzheimer's Prevention Clinic at Weill Cornell Medical College / New York - Presbyterian Hospital: Risk Stratification and Personalized Early Intervention.

Authors:  A Seifan; R Isaacson
Journal:  J Prev Alzheimers Dis       Date:  2015-10-01

4.  High-density lipoprotein mimetic peptide 4F mitigates amyloid-β-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Suresh K Swaminathan; Karunya K Kandimalla; G William Rebeck; Ling Li
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

5.  Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis.

Authors:  Andrew L Zhou; Suresh K Swaminathan; Geoffry L Curran; Joseph F Poduslo; Val J Lowe; Ling Li; Karunya K Kandimalla
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

6.  Mechanism of Lipid Binding of Human Apolipoprotein E3 by Hydrogen/Deuterium Exchange/Mass Spectrometry and Fluorescence Polarization.

Authors:  Charina S Fabilane; Patricia N Nguyen; Roy V Hernandez; Sasidhar Nirudodhi; Mai Duong; Claudia S Maier; Vasanthy Narayanaswami
Journal:  Protein Pept Lett       Date:  2016       Impact factor: 1.890

Review 7.  Peripheral versus central nervous system APOE in Alzheimer's disease: Interplay across the blood-brain barrier.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Wenhui Qu; Ling Li
Journal:  Neurosci Lett       Date:  2019-06-07       Impact factor: 3.046

Review 8.  White matter microstructure and cognitive decline in metabolic syndrome: a review of diffusion tensor imaging.

Authors:  Freddy J Alfaro; Anna Gavrieli; Patricia Saade-Lemus; Vasileios-Arsenios Lioutas; Jagriti Upadhyay; Vera Novak
Journal:  Metabolism       Date:  2017-09-08       Impact factor: 8.694

9.  RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.

Authors:  Iliya Lefterov; Jonathan Schug; Anais Mounier; Kyong Nyon Nam; Nicholas F Fitz; Radosveta Koldamova
Journal:  Neurobiol Dis       Date:  2015-06-10       Impact factor: 5.996

10.  Associations Between Hepatic Functions and Plasma Amyloid-Beta Levels-Implications for the Capacity of Liver in Peripheral Amyloid-Beta Clearance.

Authors:  Ye-Ran Wang; Qing-Hua Wang; Tao Zhang; Yu-Hui Liu; Xiu-Qing Yao; Fan Zeng; Jing Li; Fa-Yin Zhou; Lin Wang; Jia-Chuan Yan; Hua-Dong Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2016-03-09       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.